Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)

Market Cap	8.76B -49.4%
Revenue (ttm)	2.60B +0.3%
Net Income	353.15M -50.4%
EPS	0.36 -51.6%
Shares Out	950.40M
PE Ratio	25.91
Forward PE	6.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,059,460
Open	9.23
Previous Close	9.02
Day's Range	8.84 - 9.53
52-Week Range	8.54 - 19.13
Beta	0.48
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4), and human prothrombin complex concentrate, as well as intravenous cyt...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 2,755
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000403

Financial Performance

In 2025, SHE:000403's revenue was 2.63 billion, a decrease of -0.83% compared to the previous year's 2.65 billion. Earnings were 419.27 million, a decrease of -43.75%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error